NASDAQ · ASLN
ASLAN Pharmaceuticals Limited
$0.60-$0.10 (-14.27%)
ASLAN Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
Loading market information…
NASDAQ · SIEN · USD
Stock price, earnings
Quote as of Feb 21, 2024, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Sientra, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sientra, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sientra, Inc. is a global medical aesthetics firm specializing in the development and distribution of a diverse range of aesthetic medical solutions. Its core offerings encompass silicone gel implants, utilized for both breast enhancement and reconstructive surgeries, alongside breast tissue expanders and various scar management solutions. These products are marketed under prominent brands such as Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM. Beyond breast-related items, the company's portfolio extends to include products for body sculpting, facial and nasal implants, and saline-filled sizers. Sientra caters to a broad clientele, including hospitals, surgical facilities, plastic surgeons, dermatologists, and other specialized medical practitioners across the United States and internationally. Established in 2003, the enterprise was initially known as Juliet Medical, Inc., before adopting the Sientra, Inc. designation in April 2007. Its corporate headquarters are situated in Santa Barbara, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:00 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2022 | May 12, 2022 | -$2.90-11.54% vs estimate | $21.40M+2.7% vs estimate |
|---|
| Q4 2021 | Mar 23, 2022 | -$2.70-42.11% vs estimate | $22.65M+3.87% vs estimate |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.60-$0.10 (-14.27%)
ASLAN Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
$8.50+$0.50 (+6.25%)
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
$1.73-$0.02 (-1.14%)
Vyome Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.63% below the high.
$0.20$0.00 (0.0%)
Athenex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.15% below the high.
$0.85-$0.26 (-23.42%)
Fresh2 Group Limited’s quoted price sits in the lower half of its reported 52-week range, 90.56% below the high.
$0.29-$0.06 (-18.5%)
Midatech Pharma plc’s quoted price sits in the lower half of its reported 52-week range, 98.63% below the high.
$0.10$0.00 (0.0%)
Cutera, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.77% below the high.
$0.07-$0.07 (-50.87%)
VBI Vaccines Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.16% below the high.
